After demonstration of effectiveness of anti-tumour necrosis factor (TNF)-α agents in patients with rheumatoid arthritis (RA) [1-3], their use has become common practice in treating patients with RA not responding to classical disease modifying anti-rheumatic drugs (DMARDs). Here, TNF is linked to rheumatoid arthritis.